HealthDay News — For patients with drop seizures associated with Lennox-Gastaut syndrome, add-on cannabidiol is associated with a reduction in monthly drop seizure frequency, according to a study published online in The Lancet.
Elizabeth A. Thiele, MD, from Massachusetts General Hospital in Boston, and colleagues conducted a randomized trial at 24 clinical sites to examine the efficacy of cannabidiol as add-on therapy for drop seizures in 171 patients with treatment-resistant Lennox-Gastaut syndrome. Participants were randomized in a 1:1 ratio to cannabidiol (86 patients) or placebo (85 patients).
The researchers found that the median percentage reduction in monthly drop seizure frequency was 43.9% and 21.8% in the cannabidiol and placebo groups, respectively. During the 14-week treatment period, the estimated median difference between treatment groups was −17.21. Adverse events occurred in 86% and 69% of patients in the cannabidiol and placebo groups, respectively; most were mild or moderate. Diarrhea, somnolence,